A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

401

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Adenocarcinoma

Interventions

DRUG: ACR-368
DRUG: Gemcitabine
DIAGNOSTIC_TEST: OncoSignature

Sponsor

Acrivon Therapeutics

Collaborators

[object Object]